Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report released on Friday,Benzinga reports.

Other research analysts also recently issued reports about the stock. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Stock Up 11.9 %

Shares of NASDAQ LXRX opened at $0.86 on Friday. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $3.73. The stock’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.70.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same period in the previous year, the company earned ($0.21) earnings per share. As a group, analysts forecast that Lexicon Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in LXRX. CVI Holdings LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at about $34,000. Principal Financial Group Inc. boosted its stake in Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 12,225 shares during the period. Great Point Partners LLC bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $50,000. BNP Paribas Financial Markets grew its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 13,246 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 23,893 shares during the period. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.